For the year ending 2025-12-31, GRTX had -$1,914K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | 149,049 |
| Acquired in-process research and development | 0 |
| Depreciation and amortization | 0 |
| Share-based compensation expense | 410 |
| Write-off of acquired intangible asset | 0 |
| Write-off of goodwill | 0 |
| Deferred tax benefit | 0 |
| Change in fair value of warrants | -294 |
| Gain on sale of dismutase mimetics assets | 3,500 |
| Gain on extinguishment of debt | 151,049 |
| Loss on disposal of property and equipment | 0 |
| Prepaid expenses and other current assets | -357 |
| Other assets | 1 |
| Accounts payable | -1,010 |
| Accrued expenses | -11 |
| Other liabilities | 0 |
| Cash used in operating activities | -6,049 |
| Cash paid for acquisition of nova | 0 |
| Proceeds from sale of property and equipment | 0 |
| Proceeds from sale of dismutase mimetics asset | 3,500 |
| Cash provided by investing activities | 3,500 |
| Proceeds from the sale of common stock and common stock warrants in private placement, net of issuance costs | 635 |
| Cash provided by financing activities | 635 |
| Net decrease in cash and cash equivalents | -1,914 |
| Cash and cash equivalents at beginning of year | 8,289 |
| Cash and cash equivalents at end of year | 6,375 |
GRTX
GRTX